INTASYL sd RNAi dual-targeting PD-1/CTLA-4
/ Phio Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 18, 2023
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL
(PRNewswire)
- "Phio Pharmaceuticals Corp...announced that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation....Intratumoral administration of the PD-1/CTLA-4 INTASYL improved tumor control compared to either single targeting formulation, at an identical total dose. The dual-targeting formulation was well tolerated."
Preclinical • Colon Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1